1. What risk/s does an infant born to a mother positive for HBsAg have?
The precise mechanism of HBV transmission remains unclear, but it appears that infection may occur intrapartum or, rarely, in utero. Hepatitis B viral DNA and HBsAg have been detected in amniotic fluid, placental cells, and vaginal secretions of HBsAg-positive women during pregnancy and in cord blood of their neonates
Three possibilities of transmission of HBV from carrier mothers to newborns are suggested: (a) transplacental transmission in utero - it was estimated that such transmission occurred in 5-15% of newborns; (b)
transmission during delivery, which is considered the main mode of perinatal transmission; (c) postnatal transmission from mother to newborn, which is not common.
The overall rate of transmission of HBV from an infected HBsAg-positive mother to her neonate during the perinatal period ranges from 5-90% in the absence of immunoprophylaxis [2,4-7]. This risk depends on whether the mother also has a positive hepatitis B e antigen (HBeAg) test; those with a positive HBeAg test have a transmission rate of 70-90%, whereas those with a negative HBeAg test have a rate of transmission less than 10% [2]. In these mothers with HBeAg, the risk of HBV perinatal transmission is reduced from 70-90% to approximately 5-15% when the infant receives postnatal immunoprophylaxis with both hepatitis B immune globulin (HBIG) and hepatitis B vaccine series [5,6]; the risk is reduced to approximately 20% with regimens that use multiple doses of HBIG only or the vaccine series alone [1,2, 4-6]. Although controlled trials have not been performed with HBeAg-negative women, postexposure prophylaxis with HBIG and vaccination would presumably further minimize the risk of transmission.
Most neonates with HBV infection are asymptomatic but develop chronic, subclinical hepatitis characterized by persistent HBsAg antigenemia and variably elevated transaminase activity.
Many born to women with acute hepatitis B during pregnancy are of low birth weight, regardless of whether they are infected.Infrequently, infected neonates develop acute hepatitis B, which is usually mild and self-limited. They develop jaundice, lethargy, failure to thrive, abdominal distention, and clay-colored stools. Occasionally, severe infection with hepatomegaly, ascites, and hyperbilirubinemia (primarily conjugated bilirubin) occurs. Rarely the disease is fulminant and even fatal. Fulminant disease occurs more often in neonates whose mothers are chronic carriers of hepatitis B.
2. In the case, the mother was not immediately tested fro HBaAg. Ideally,
when should pregnant women be tested for HBsAg?
*
Test all pregnant women at the first prenatal visit for hepatitis B surface antigen (HBsAg). * Women admitted for delivery who have not had prenatal HBsAg testing should have blood drawn for testing [5].
* Send a copy of the original lab report to the hospital.
* “More than 90% of women found to be HBsAg-positive on routine screening will be HBV carriers, routine follow-up testing later in pregnancy is not necessary for the purpose of screening. In special situations, such as when the mother is thought to have acute hepatitis, when there has been a history of exposure to hepatitis, or when particularly high-risk behavior such as parenteral drug abuse has occurred during the pregnancy, an additional HBsAg test can be ordered during the third trimester” [6]
* Test all susceptible contacts (including all family members) with hepatitis B panel (HBsAg, antiHBc, antiHBs).
* Screening and vaccination of susceptible contacts should be done by the family's pediatrician, primary health-care provider, or the physician evaluating the clinical status of the HBsAg-positive pregnant women.
•
Health-care providers should test all pregnant women for HBsAg during each pregnancy.• HBsAg testing should be incorporated into standard prenatal testing panels (e.g., blood type, HIV infection, Rh factor, rubella antibody titer, syphilis infection) used by all practitioners caring for pregnant women.
•
Women who test negative for HBsAg but have risk factors (>1 sex partner in past 6 months, evaluation or treatment for a sexually transmitted disease, recent or current injection-drug use, HBsAg-positive sex partner) should be vaccinated against hepatitis B and should be retested in the third trimester.3. What is the correct medical management for this woman, having known that she was positive for HBsAg?
What is a possible adverse effect of treatment on the fetus? What happens to the baby if the vaccine is not received on time?
The treatment of acute HBV infection is supportive.Persons with chronic hepatitis B should be referred to health-care professionals with experience in the treatment of hepatitis B for treatment with alpha-interferon or lamivudine [1].
Interferon does not appear to adversely affect the embryo or fetus. However, the data is limited, and the potential benefits of interferon use during pregnancy should clearly outweigh possible hazards [7-9].
Initial data do not suggest that Lamivudine is teratogenic [10]. Lamivudine has been used in the latter half of pregnancy in attempt to prevent perinatal transmission of hepatitis B virus infection with mixed success [11,12]
There is a certain risk that if a child at danger is not immunised, it may develop into a chronic carrier and eventually produce liver damage.
Some sources proved that delayed vaccination schedules are not less effective than immunization beginning right after birth. A 1993 article (18) states that "late active immunization starting at 3 months of age appears to provide similar protective efficacy as active immunization starting at birth when combined with hepatitis B immune globulin at 0 and 3 months of age." Passively acquired antibodies at birth (immune globulines) remained present for about five months in most infants (19). 18. Am J Dis Child, 1993; 147/12:1316-20 19. Vaccine, 1994; 12/12:1059-63
4. What are important considerations in handling and administration of hepatitis B vaccines.
Administer 0.5 mL hepatitis B vaccine intramuscularly in the anterolateral thigh muscle for infants
Choose needle length appropriate to the child’s
age and body mass: newborns (first 28 days of life) and premature infants: e"; infants younger than age 12 mos: 1"; toddlers
1–2 yrs: 1–13" (anterolateral thigh) or e–1" (deltoid muscle);
It is necessary to give 4 doses of HepB when Comvax or Pediarix vaccines are given after the
birth dose.
5. Upon knowing that a mother is positive for HBsAg, how will you care for her during the intrapartal period?
AT THE TIME OF ADMISSION
• Review the hepatitis B surface antigen (HBsAg) status of all pregnant women admitted for labor and delivery.
• Accept only laboratory reports as documentation of hepatitis B status.
• Perform HBsAg testing as soon as possible if there is no documentation of the woman’s HBsAg status or if she has clinical hepatitis.
• Retest women who are known to have engaged in behaviors that put them at risk for acquiring hepatitis B infection during pregnancy (e.g., recent intravenous drug use, an HBsAg-positive sex partner, more than one sex partner in the past 6 months, or treatment for a sexually transmitted disease).
Pregnant women who present at delivery with unknown HBsAg status should have blood drawn at that time for HBsAg testing. In most states, hepatitis B infection in pregnancy is a reportable condition, and state and local public health departments have programs to provide education and follow-up for HBsAg positive women and their children. Mothers who have a positive HBsAg test should undergo evaluation to determine if they have evidence of chronic liver disease. To facilitate immunoprophylaxis of a woman who is HBsAg seropositive, provide a copy of her laboratory report to her delivery hospital and/or the obstetrical provider that will attend her devlivery, as well as the healthcare provider who will care for her neonate.
6. What is the preferred method of delivery in pregnant women found positive for HBsAg? Why?
The mode of delivery (vaginal versus caesarean) does not appear to have an impact on the risk for perinatal HBV infection. Although cesarean delivery has been proposed as a means of reducing mother to child transmission (MCT) of HBV, the mode of delivery does not appear to have a significant effect on the interruption of HBV maternal-baby transmission by immunoprophylaxis. Delivery by cesarean section for the purpose of reducing MCT of HBV is note presently recommended by either the CDC or the ACOG.
7. Should breastfeeding be encouraged?
Transmission of HBV through breast milk is not a significant source of infection, as demonstrated by several small studies performed before the era of routine neonatal prophylaxis [12,13]. With appropriate hepatitis B immunoprophylaxis,
breast-feeding poses no additional risk for transmission from infected hepatitis B virus carriers [17,18] However, if a mother has cracked nipples, abscesses, or other breast pathology, breastfeeding could potentially transmit HBV.References:
J Virol Methods. 1987 Aug;17(1-2):69-79. Perinatal transmission of hepatitis B virus in high-incidence countries. Ghendon Y. World Health Organization, Geneva, Switzerland.
Neonatal Hepatitis B Virus Infection
Labor and Delivery Unit and Nursery Unit Guildelines to Prevent Hepatitis B Virus Transmission
Components of Case Management Programs to Prevent Perinatal Hepatitis B Virus (HBV) Infection
Hepatitis B Infection
Hepatitis-B vaccination in newborns Kris Gaublomme, MD
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States
Standing Orders for Administering Hepatitis B Vaccine to Children & Teens
Preventing Perinatal Hepatitis B Guidelines for Labor and Delivery Units
Recommendations of the Immunization Practices Advisory Committee Prevention of Perinatal Transmission of Hepatitis B Virus: Prenatal Screening of all Pregnant Women for Hepatitis B Surface Antigen